These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 6756508

  • 1. Randomized clinical trial of tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal women with advanced breast cancer.
    Glick JH, Creech RH, Torri S, Holroyde C, Brodovsky H, Catalano RB, Varano M.
    Breast Cancer Res Treat; 1981; 1(1):59-68. PubMed ID: 6756508
    [Abstract] [Full Text] [Related]

  • 2. Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial.
    Glick JH, Creech RH, Torri S, Holroyde C, Brodovsky H, Catalano RB, Varano M.
    Cancer; 1980 Feb 15; 45(4):735-41. PubMed ID: 6986969
    [Abstract] [Full Text] [Related]

  • 3. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
    International Breast Cancer Study Group (IBCSG).
    J Natl Cancer Inst; 2002 Jul 17; 94(14):1054-65. PubMed ID: 12122096
    [Abstract] [Full Text] [Related]

  • 4. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
    Tormey DC, Gray R, Gilchrist K, Grage T, Carbone PP, Wolter J, Woll JE, Cummings FJ.
    Cancer; 1990 Jan 15; 65(2):200-6. PubMed ID: 2403834
    [Abstract] [Full Text] [Related]

  • 5. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
    Boccardo F, Rubagotti A, Bruzzi P, Cappellini M, Isola G, Nenci I, Piffanelli A, Scanni A, Sismondi P, Santi L.
    J Clin Oncol; 1990 Aug 15; 8(8):1310-20. PubMed ID: 2199618
    [Abstract] [Full Text] [Related]

  • 6. Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study.
    Cocconi G, De Lisi V, Boni C, Mori P, Malacarne P, Amadori D, Giovanelli E.
    Cancer; 1983 Feb 15; 51(4):581-8. PubMed ID: 6336981
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.
    International Breast Cancer Study Group.
    J Clin Oncol; 1997 Apr 15; 15(4):1385-94. PubMed ID: 9193330
    [Abstract] [Full Text] [Related]

  • 8. Treatment of metastatic breast cancer in estrogen receptor positive patients. A randomized trial comparing tamoxifen alone versus tamoxifen plus CMF.
    Bezwoda WR, Derman D, De Moor NG, Lange M, Levin J.
    Cancer; 1982 Dec 15; 50(12):2747-50. PubMed ID: 6754067
    [Abstract] [Full Text] [Related]

  • 9. Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifen.
    Mouridsen HT, Rose C, Engelsman E, Sylvester R, Rotmensz N.
    Eur J Cancer Clin Oncol; 1985 Mar 15; 21(3):291-9. PubMed ID: 3891357
    [Abstract] [Full Text] [Related]

  • 10. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.
    Aebi S, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Lindtner J, Snyder R, Karlsson P, Simoncini E, Gusterson BA, Viale G, Regan MM, Coates AS, Goldhirsch A.
    Ann Oncol; 2011 Sep 15; 22(9):1981-1987. PubMed ID: 21282282
    [Abstract] [Full Text] [Related]

  • 11. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.
    Pritchard KI, Paterson AH, Fine S, Paul NA, Zee B, Shepherd LE, Abu-Zahra H, Ragaz J, Knowling M, Levine MN, Verma S, Perrault D, Walde PL, Bramwell VH, Poljicak M, Boyd N, Warr D, Norris BD, Bowman D, Armitage GR, Weizel H, Buckman RA.
    J Clin Oncol; 1997 Jun 15; 15(6):2302-11. PubMed ID: 9196144
    [Abstract] [Full Text] [Related]

  • 12. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor.
    Colleoni M, Li S, Gelber RD, Coates AS, Castiglione-Gertsch M, Price KN, Lindtner J, Rudenstam CM, Crivellari D, Collins J, Pagani O, Simoncini E, Thürlimann B, Murray E, Forbes J, Erzen D, Holmberg S, Veronesi A, Goldhirsch A.
    Ann Oncol; 2005 May 15; 16(5):716-25. PubMed ID: 15817593
    [Abstract] [Full Text] [Related]

  • 13. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
    Ejlertsen B, Jensen MB, Elversang J, Rasmussen BB, Andersson M, Andersen J, Nielsen DL, Cold S, Mouridsen HT.
    Eur J Cancer; 2013 Sep 15; 49(14):2986-94. PubMed ID: 23756360
    [Abstract] [Full Text] [Related]

  • 14. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial.
    Boccardo F, Rubagotti A, Amoroso D, Sismondi P, Genta F, Nenci I, Piffanelli A, Farris A, Castagnetta L, Traina A.
    Eur J Cancer; 1992 Sep 15; 28(2-3):673-80. PubMed ID: 1591091
    [Abstract] [Full Text] [Related]

  • 15. Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients. A randomized trial.
    Viladiu P, Alonso MC, Avella A, Beltrán M, Borrás J, Ojeda B, Bosch FX.
    Cancer; 1985 Dec 15; 56(12):2745-50. PubMed ID: 3902200
    [Abstract] [Full Text] [Related]

  • 16. Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.
    Bianco AR, De Placido S, Gallo C, Pagliarulo C, Marinelli A, Petrella G, D'Istria M, Delrio G.
    Lancet; 1988 Nov 12; 2(8620):1095-9. PubMed ID: 2903322
    [Abstract] [Full Text] [Related]

  • 17. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
    International Breast Cancer Study Group (IBCSG)International Breast Cancer Study Group Coordinating Center and Inselspital, Bern, Switzerland. monica.castiglione@siak.ch, Castiglione-Gertsch M, O'Neill A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Nasi ML, Bonetti M, Gelber RD.
    J Natl Cancer Inst; 2003 Dec 17; 95(24):1833-46. PubMed ID: 14679153
    [Abstract] [Full Text] [Related]

  • 18. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
    Kaufmann M, Jonat W, Abel U, Hilfrich J, Caffier H, Kreienberg R, Trams G, Brunnert K, Schermann J, Kleine W.
    J Clin Oncol; 1993 Mar 17; 11(3):454-60. PubMed ID: 8445420
    [Abstract] [Full Text] [Related]

  • 19. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
    Taylor SG, Kalish LA, Olson JE, Cummings F, Bennett JM, Falkson G, Tormey DC, Carbone PP.
    J Clin Oncol; 1985 Feb 17; 3(2):144-54. PubMed ID: 3881561
    [Abstract] [Full Text] [Related]

  • 20. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
    CMAJ; 1998 Feb 10; 158 Suppl 3():S52-64. PubMed ID: 9484279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.